Preface

Dermatology is an experimenting discipline. While new treatments for specific diseases keep getting registered, we still have a shortage of treatments for many skin conditions. It is thus rather the rule than the exception to adopt treatment strategies available to unregistered indications as off-label use in our specialty. Dermatologists also excel in personalizing medicine for their patients by adapting registered treatment protocols to fit their patient needs while achieving clinical improvement.

Here, we present to you a collection of cases in which the substance ingenol mebutate that was recently registered for the treatment of actinic keratosis is put to use with regimens deviating from the registered ones and also beyond the realm of actinic keratoses. The authors

have varied their application schemes to accommodate for larger treatment fields, the use of ingenol mebutate with occlusion and with a reduced number of applications to treat actinic keratoses. Other cases illustrate the authors' experience in conditions beyond actinic keratoses such as Bowen's disease, warts, basal cell carcinoma and lentigo maligna. While a case report does not prove efficacy on its own, case reporting is an important first step in the discovery of new uses and treatment regimens for ingenol mebutate. We hope to inspire the readers with our collection of cases to do what dermatologists do best – personalize medicine for our patients.

Günther F.L. Hofbauer, Zurich